Kelly Jared 4

What Happened Kelly Jared, CEO of Oncolytics Biotech Inc. (ONCY), reported an acquisition of 5,050 shares on 2026-03-12. The filing lists the transaction as a purchase (code P) at $0.96 per share, for a total cash outlay of approximately $4,848. This was a buy (insider acquisition), which investors often view as a more informative signal than routine sales, though motivations are not disclosed.

Key Details

• Transaction date: 2026-03-12; Filing date: 2026-03-13 (Form 4 filed the next day, appearing timely).
• Price and amount: 5,050 shares at $0.96 per share; total ≈ $4,848.
• Transaction type: Reported as an open-market/private purchase (code P on the Form 4).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnotes / plans: No 10b5-1 plan, tax withholding, or other special footnotes were indicated in the provided transaction details.

Context This is a small-dollar insider purchase rather than a large institutional stake; such buys can indicate confidence but are not definitive proof of future performance. The filing appears timely (filed the next day), and there’s no indication the shares were acquired via option exercise, gift, or tax-related transfer.